Precision BioSciences (DTIL)
(Delayed Data from NSDQ)
$8.94 USD
-0.02 (-0.22%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $8.93 -0.01 (-0.11%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.94 USD
-0.02 (-0.22%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $8.93 -0.01 (-0.11%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth B Momentum A VGM
Zacks News
Precision BioSciences (DTIL) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 194.74% and 202.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences (DTIL) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precision BioSciences (DTIL) Surges 6.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 32.65% and 86.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 12.00% and 136.97%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Precision BioSciences (DTIL) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precision BioSciences' (DTIL) New Lymphoma Drug IND Gets FDA Nod
by Zacks Equity Research
The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.
Lilly (LLY) Inks Deal With Merus to Discover Cancer Antibodies
by Zacks Equity Research
Eli Lilly (LLY) signs a deal with Merus to develop novel T-cell re-directing bispecific antibodies. While Merus will lead early-stage development, Loxo Oncology will take care of further development and commercialization.
Lilly's (LLY) Coronavirus Treatment Gets Interim Nod in Canada
by Zacks Equity Research
Lilly's (LLY) antibody drug bamlanivimab wins interim authorization from Health Canada to treat COVID-19. The company inks a genome editing research collaboration deal with Precision BioSciences.
Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 26.47% and 73.25%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Precision BioSciences (DTIL) Q3 Earnings Expected to Decline
by Zacks Equity Research
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precision BioSciences (DTIL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -5.00% and -80.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Precision BioSciences (DTIL) Q2 Earnings Expected to Decline
by Zacks Equity Research
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 1.89% and 34.71%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences (DTIL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Precision BioSciences (DTIL) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Precision BioSciences (DTIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precision BioSciences, Inc. (DTIL) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Precision BioSciences, Inc. (DTIL).